Aim: Hepatic innervation represents a potentially underestimated regulator of liver function and regeneration. The muscarinic 3 receptor (M 3 -R) is the primary cholangiocyte receptor for the afferent parasympathetic innervation of bile ducts. We aimed to determine the specific role of the M 3 -R in bile formation and models for cholestatic liver disease in mice. 
INTRODUCTION
Cholangiopathies remain an important cause of liver disease with a largely enigmatic pathophysiology. 1 Consequently, treatment methods for prototypic cholangiopathies such as primary sclerosing cholangitis, secondary sclerosing cholangitis of critically ill patients, and primary biliary cholangitis (PBC) unresponsive to ursodeoxycholic acid are limited. 2 Novel therapeutic approaches, such as blockers of the synthesis and enterohepatic circulation of bile acids (BAs), are under investigation as novel therapies in cholestatic liver diseases (e.g. farnesoid X receptor agonists, apical sodium-dependent BA transporter, and sodium taurocholate cotransporting polypeptide blockers). [2] [3] [4] [5] [6] [7] Cholangiopathies are, however, complex diseases comprising inflammatory, adaptive, and regenerative responses and thus, successful treatment will most likely require combinations of different drugs at different time points of the disease course.
The "toxic bile" hypothesis was primarily promoted by Piet Borst and colleagues based on their milestone development of Mdr2 À/À mice that lack phospholipids in bile. This represents a conceptual model for the pathogenesis of specific cholangiopathies, suggesting that hydrophobic bile salt-induced cytotoxicity plays a major role in initiating and perpetuating bile duct injury.
victims in cholangiopathies, these cells are accustomed to exposure to millimolar concentrations of hydrophobic bile salts without any evidence of BA-induced cytotoxicity under physiologic conditions. 9, 10 Hence, normal bile duct epithelial cells appear perfectly adapted to the harsh environment within the bile duct. These highly specialized epithelial cells can modify bile by specific transport capacities, particularly for bicarbonate (HCO 3 À ).
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The secretory and absorptive properties of cholangiocytes are regulated by a variety of hormones, signaling molecules, and the autonomic nervous system. 16, 17 Experimental vagal stimulation increases bile flow and biliary HCO 3 À excretion, whereas vagotomy decreases basal bile flow and biliary HCO 3 À output. [18] [19] [20] The parasympathetic regulation of cholangiocytes is mediated by the muscarinic 3 receptor (M 3 -R), which represents the primary cholangiocyte receptor for afferent parasympathetic innervation. 16 The M 3 -R is located at cholangiocyte cell membrane invaginations, independent of cell size, suggesting an important role in regulating bile duct functions. 21 Intrahepatic parasympathetic nerve terminations release acetylcholine (ACh), which interacts selectively with the M 3 -R expressed on the basolateral membrane of cholangiocytes. Activation of the M 3 -R leads to increase in intracellular inositol 1,4,5-trisphosphate (IP-3), causing Ca 2+ release from the endoplasmic reticulum, which activates the Ca/Cl channel pivotal for Cl À /HCO 3 À anion exchanger 2 (AE2) stimulation. 22 By this mechanism ACh can potentiate the effect of secretin on bile flow with a net effect of increasing biliary HCO 3 À secretion. 11, 16 Consequently, we hypothesized that defective M 3 -R signaling may result in decreased biliary HCO À 3 secretion and increase cholangiocyte susceptibility to BA-induced cell injury. However, this concept has not been tested in model systems.
Several observations suggest a potential role for M 3 -R in the pathogenesis of cholestatic liver diseases and that it could be an attractive therapeutic target, considering: (i) patients with PBC frequently show autoantibodies directed against the human muscarinic acetylcholine receptor of the M 3 type; 23 (ii) in PBC, altered AE2 function may result in reduced biliary HCO 3 secretion; 19, 24, 25 (iii) transplanted, denervated livers show increased susceptibility to bile duct ischemia; 26 (iv) denervation of donor livers may favor anastomotic and non-anastomotic bile duct strictures, which remain a frequent and difficult post-transplant complication; 27 (v) bile duct ischemia together with impaired M 3 -R signaling may also be important in the pathogenesis of secondary sclerosing cholangitis of critically ill patients -these patients frequently require high-dose catecholamine treatment, leading to an imbalance between the sympathetic and parasympathetic nervous systems; 28 
Bile flow and composition
To determine the physiological role of the M 3 -R in bile formation, bile flow and bile composition were determined in 8-week-old M 3 -R À/À and WT mice. Mice were anesthetized and a longitudinal incision were made in each abdomen. The common bile duct was ligated, and the gallbladder cannulated for collection of bile. After a 10-min equilibration period, bile was collected for 1 h in test tubes containing mineral oil for determination of HCO 3 À , total carbon dioxide, and pH using an automatic blood gas analyzer (AVL 995 hp; AVL, Graz, Austria; COBAS Mira plus, Roche, Vienna, Austria). For bile flow measurements and additional bile analysis, bile was collected for the subsequent 30 min in pre-weighed test tubes. Bile flow was determined gravimetrically and normalized to liver weight. Biliary phospholipid concentration was determined using a commercially available kit (Phospholipid B; Wako, Neuss, Germany). In brief, 5 μL bile was mixed with 750 μL color reagent and incubated for 10 min at 37°C and measured at 505 nm. Concentrations were determined using the standard solution provided with the kit. Biliary cholesterol concentrations were determined using a commercially available kit (Cholesterol LiquiColor; Human, Wiesbaden, Germany) according to the manufacturer's instructions. Biliary BA concentration required bile to be diluted 1:300 in physiological saline and analyzed using a 3α-hydroxysteroid dehydrogenase assay (Ecoline S + ; DiaSys, Holzheim, Germany) according to the manufacturer's instructions.
Chronic feeding of 3, 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)
To determine the role of the M 3 -R in acquired cholangiopathies, we compared liver injury in M 3 -R À/À and WT mice after 17 days of 0.1% DDC feeding. 3, 5-Diethoxycarbonyl-1,4-dihydrocollidine is a wellcharacterized model for xenobiotic-induced cholangitis with ductular recation and onion skin type-like periductal fibrosis. 31, 32 It induces segmental subtotal mechanical bile duct obstruction by porphyrin plugs and leads to transformation of cholangiocytes into a reactive phenotype secreting cytokines. The resulting inflammation stimulates neutrophil infiltration in the portal field and activates periductal myofibroblasts, leading to a ductal reaction and sclerosing cholangitis.
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Mdr2 knockout (Mdr2 À/À ) mice represent a genetic model for sclerosing cholangitis and biliary fibrosis. In these mice, the lack of biliary phospholipids results in decreased micelle formation and, consequently, increased biliary concentration of monomeric bile acids, 8 leading to bile duct injury and chronic sclerosing cholangitis with periductal inflammation and onion skin-like periductal fibrosis starting at 4 weeks of age. 33, 34 These changes share several important morphologic and pathogenetic features with human sclerosing cholangitis (e.g. primary sclerosing cholangitis). 34 To determine whether the liver phenotype in Mdr2
À/À mice can be altered by treatment with a muscarinic M 3 -R agonist, 4-week-old Mdr2 À/À mice and respective controls (Mdr2 +/+ mice) received bethanechol (400 μg/mL) in their drinking water for 4 weeks. 35 We compared these mice with an untreated control group of Mdr2 À/À mice and WT littermates. Mice were freely allowed to drink water with or without bethanechol (without gavage) for 4 weeks. Volumes of water consumed by each group were measured weekly and were not significantly different between the groups during the study period. In addition, to determine whether bethanechol treatment alters bile flow and biliary HCO 3 À secretion, 
Serum biochemical analysis and liver histology
Serum samples were analyzed for alanine aminotransferase (ALT), alkaline phosphatase, and total serum BA using a Cobas 501 analyzer (Roche Diagnostics, Mannheim, Germany). For conventional light microscopy, livers were fixed in 3.7% neutral buffered formaldehyde solution and embedded in paraffin. Sections (2 mm thick) were stained with hematoxylin-eosin and Sirius Red.
Measurement of hepatic hydroxyproline content
Liver fibrosis was quantified by measuring hepatic hydroxyproline concentration by a calorimetric method. In brief, mouse liver lobe 3 (left liver lobe) was homogenized in 6 N HCl and hydrolyzed overnight at 110°C. Hydrolyzates were filtered, neutralized with NaOH, and oxidized with chloramine-T. This was followed by a reaction with perchloric acid and p-dimethylaminobenzaldehyde, resulting in the formation of a chromophore quantified photometrically at 565 nm. 36 
Determination of hepatic mRNA levels
For the quantitative polymerase chain reaction, RNA was extracted and reverse transcribed. Polymerase chain reaction (20 μL) contained 12.5 ng cDNA, 330 nM each primer, and 10.5 lL SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA). Expression levels of all transcripts were normalized to the housekeeping gene S18. (Fig. 1a) . Moreover, liver histology was comparable throughout the groups. Similar to WT controls, M 3 -R À/À mice did not develop obvious liver injury with age (Fig. 1b) , and did not show signs of spontaneous liver fibrosis of the biliary type (Fig. 1c,d ). Together these findings suggest that genetic loss of M 3 -R does not alter liver morphology or function in aging mice.
Statistical analysis

Loss of M 3 -R results in increased susceptibility to DDC-induced cholestasis
We next challenged mice with DDC to test the hypothesis that M 3 -R À/À mice are more vulnerable to bile duct injury.
Both M 3 -R À/À and WT control mice were fed 0.1% DDC-supplemented diet for 17 days to determine whether ). Biliary phospholipid and bile acid secretion were similar in both groups. LW, liver weight. vs. WT, P < 0.05) levels compared to those in WT controls (Fig. 2) . Liver histology of DDC-fed M 3 -R À/À and WT control mice showed comparable ductal reaction (Fig. 3a) . However, livers of M 3 -R À/À mice contained more and larger porphyrin plugs compared to WT mice (Fig. 3, black  arrows) . The M 3 -R À/À mice lost more body weight (BW) compared to WT controls (baseline BW 25.2 ± 0.7 g and BW after DDC feeding 17.4 ± 0.8 g vs. baseline BW 25.5 ± 2.9 g and BW after DDC feeding 24.7 ± 2.7, for M 3 -R À/À vs. WT mice, respectively, P < 0.05) (Fig. 4a) . However, differences in liver fibrosis between the two genotypes, as suggested by Sirius Red staining (Fig. 3b) , did not translate into significant differences in hepatic hydroxyproline levels (Fig. 4b ) or mRNA levels of col1a1 and tgfβ1 (Fig. 4c) without bethanechol, P > 0.05) (Fig. 5a) . During bethanechol treatment, Mdr2 À/À mice gained significantly more BW compared to untreated control mice (gain of BW 3.5 ± 1.3 mg vs. 0.5 ± 1.1, Mdr2 À/À with bethanechol vs. Mdr2 À/À without bethanechol, P < 0.05) (Fig. 5b) . Comparing liver histology of Mdr2 À/À mice with and without bethanechol treatment revealed no detectable difference (Fig. 6a) . Liver fibrosis based on hepatic hydroxyproline levels was similar in both groups (Fig. 6b) . Taken together, 4 weeks of treatment with the M 3 -R agonist bethanechol resulted in some amelioration of cholestasis and liver injury in Mdr2 ; KO) and wild-type (WT) mice after 17 days of 3, 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) feeding. M 3 -R À/À mice showed significantly higher serum alanine aminotransferase (ALT), bilirubin (Bili), and bile acid (BA) levels compared to WT mice after 17 days DDC feeding. M 3 -R À/À mice are more susceptible to liver injury after DDC feeding compared to WT mice. *P < 0.05 versus control. AP, alkaline phosphatase.
(Mdr2 +/+ mice) received bethanechol in drinking water for 1 week. Thereafter, bile flow and biliary HCO 3 À output was measured. In this experimental setting, bethanechol treatment did neither significantly increase bile flow nor biliary HCO 3 À output in Mdr2 ; KO) and wild-type (WT) mice after 17 days of feeding with 3, 5-diethoxycarbonyl-1,4-dihydrocollidine. Ductal reaction and liver fibrosis were similar in both groups. Note that there is subtotal obstruction of bile ducts by porphyrin plugs as well as increased porphyrin accumulation in bile duct lumina of M 3 -R À/À compared to WT mice (arrow). Original magnification, ×20. bd, bile duct; PV, portal vein.
Role
Taken together, these data indicate that the beneficial effects of bethanechol in Mdr2 À/À mice may not primarily be related to increased biliary HCO 3 À secretion.
DISCUSSION
A LTERED BILIARY HCO 3 À secretion due to defective M 3 -R signaling in cholangiocytes may increase susceptibility for bile duct injury. As cholangiocytes are physiologically exposed to high concentrations of potentially toxic BAs, they have developed defense mechanisms to adapt to their harsh environment. Bile acids are actively secreted into the canalicular lumen almost exclusively through ATP-binding cassette, sub-family B member 11 (bile salt export pump) and form mixed micelles together with phospholipids and cholesterol. 37 Biliary HCO 3 À secretion mediated primarily through the interplay of cystic fibrosis transmembrane regulator and AE2 is an important component of BAindependent bile flow. 22 In addition, HCO 3 À secretion may stabilize the glycocalyx of cholangiocytes, which is sometimes referred to as the "HCO 3 À umbrella". 38 Consequently, altered HCO 3 À secretion due to deficient expression or activation of M 3 -R signaling may weaken this protective shield of cholangiocytes, possibly representing a first or second hit in the pathobiology of cholangiopathies. To test this hypothesis experimentally, we assessed the impact of genetic loss of the M 3 -R on bile formation and cholestatic liver injury in mice. We herein showed that the muscarinic M 3 -R plays an essential role in bile formation. Mice lacking the M 3 -R showed significantly reduced bile flow, which may originate primarily from decreased biliary HCO 3 À secretion. This observation is of physiological relevance, as it underscores the relative importance of normal M 3 -R signaling for physiological bile formation, especially for the BA-independent fraction of bile flow. In general, bile flow is generated by an osmotic water flow in response to active solute transport. 22 Cholangiocytes are equipped with numerous transporter proteins that dilute and alkalinize bile during its passage along the biliary tree. 39 On their apical membrane, cholangiocytes express AE2, which transports HCO 3 À into the bile duct lumen in exchange for Cl À . 19, 40 Secretion of HCO 3 À is followed by osmotically driven efflux of water into the ductal lumen by the aquaporine channel AQ1. 40 Activation of the M 3 -R leads to increase in intracellular IP-3 causing Ca 2+ release from the endoplasmatic reticulum which activates the Ca/Cl channel pivotal for AE2 activation. 22 Consequently, the reduction of biliary HCO 3 À output may result, due to altered secretin signaling that possibly modulates the biliary HCO 3 À output.
To evaluate the effects of genetic loss of the M 3 -R on bile duct susceptibility to injury, we compared liver injury in DDC-fed M 3 -R À/À and WT littermates. After 17 days of DDC feeding, M 3 -R À/À mice had more liver injury, accompanied by more pronounced intraductal protoporphyrin IX plugs. The solubility of porphyrins critically depends on the environmental pH. 42 Consequently, it is reasonable that aggravated liver injury in M 3 -R À/À mice is the result of primarily diminished biliary HCO 3 À secretion and the resulting lower biliary pH. The observed difference in BW between the two genotypes in response to DDC feeding may be primarily related to the increased susceptibility of M 3 -R À/À mice. 43 Muscarinic receptors are targets of the pharmacological therapy for different diseases like chronic obstructive pulmonary disease, 44 glaucoma, 45 and Sjörgen's syndrome. 46 To test the effect of a muscarinic receptor agonist in cholestatic liver disease, we compared liver injury of Mdr2 À/À mice treated with bethanechol versus untreated controls. After 4 weeks, bethanechol-treated Mdr2 À/À mice showed less liver injury and cholestasis, as evidenced by the decline of liver serum parameters, compared to untreated controls. However, no significant effect on liver fibrosis was detectable and there was no significant increase in bile flow or biliary HCO 3 À output after 1 week of bethanechol treatment. Consequently, the Bethanechol did not result in a significant increase of bile flow or biliary HCO 3 À output compared to untreated controls (74.7 ± 20.0 vs.
61.0 ± 8.6 U/L, Mdr2 À/À with bethanechol vs. Mdr2 À/À without bethanechol, P > 0.05). Bethanechol treatment had no effect on bile flow or biliary HCO 3 À secretion in Mdr2 +/+ mice. LW, liver weight.
Role of the muscarinic M 3 
